Takeda Pharmaceutical Company Limited (TYO: 4502)
Japan
· Delayed Price · Currency is JPY 4,045.00
+13.00 (0.32%)
Jan 21, 2025, 2:47 PM JST
Takeda Pharmaceutical Company Revenue
Takeda Pharmaceutical Company had revenue of 1.18T JPY in the quarter ending September 30, 2024, with 12.75% growth. This brings the company's revenue in the last twelve months to 4.55T, up 9.43% year-over-year. In the fiscal year ending March 31, 2024, Takeda Pharmaceutical Company had annual revenue of 4.26T with 5.87% growth.
Revenue (ttm)
4,546.08B
Revenue Growth
+9.43%
P/S Ratio
1.40
Revenue / Employee
92.25M
Employees
49,281
Market Cap
6,400.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | 3,291.19B | 1,193.96B | 56.93% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,142.35B |
| Daiichi Sankyo Company | 1,758.07B |
| HOYA Corporation | 812.74B |
| Otsuka Holdings | 2,269.56B |
| Terumo | 986.67B |
| Astellas Pharma | 1,772.16B |
| Olympus | 973.60B |
| Shionogi & | 418.51B |
Takeda Pharmaceutical Company News
- 24 days ago - Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency - Benzinga
- 25 days ago - Takeda Pharmaceutical Co Ltd (TAK) Secures Approval for HYQVIA in Japan - GuruFocus
- 25 days ago - Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia - Benzinga
- 25 days ago - Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia - Business Wire
- 5 weeks ago - Takeda Pharmaceutical Co Ltd (TAK) Unveils Promising Late-Stage Pipeline at Investor R&D Day - GuruFocus
- 5 weeks ago - Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas - Business Wire
- 6 weeks ago - Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors - Seeking Alpha
- 6 weeks ago - Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst - Benzinga